Cargando…

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenqi, Huang, Chen, Liu, Ruixia, Zhang, Huichao, Li, Weijing, Yin, Shaoning, Wang, Lianjing, Liu, Wei, Liu, Lihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581047/ https://www.ncbi.nlm.nih.gov/pubmed/36275715 http://dx.doi.org/10.3389/fimmu.2022.983934

Ejemplares similares

Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis
por: Zhang, Wenqi, et al.
Publicado: (2022)

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
por: Zou, Rui, et al.
Publicado: (2023)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report
por: Feng, Lan, et al.
Publicado: (2022)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
por: Cao, Tingyu, et al.
Publicado: (2022)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review
por: Li, Weijing, et al.
Publicado: (2020)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report
por: Zhou, Ying, et al.
Publicado: (2023)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
por: Epperla, Narendranath, et al.
Publicado: (2023)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study
por: Huang, Chen, et al.
Publicado: (2020)

Prevention and management of secondary central nervous system lymphoma
por: Bobillo, Sabela, et al.
Publicado: (2022)

P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY
por: Shadman, Mazyar, et al.
Publicado: (2023)

Miliary pattern in secondary central nervous system T-cell lymphoma
por: Rajendran, Sibi, et al.
Publicado: (2022)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Yang, Junfang, et al.
Publicado: (2023)

CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes
por: Lacan, Claire, et al.
Publicado: (2023)

Association Between Polymorphism in Diabetes Susceptibility Gene Insulin-Like Growth Factor 2mRNA–Binding Protein 2 and Risk of Diffuse Large B-Cell Lymphoma
por: Zhou, Weiling, et al.
Publicado: (2023)

The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen, and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report
por: Zhou, Weiling, et al.
Publicado: (2023)

Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report
por: Li, Qian, et al.
Publicado: (2021)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Secondary central nervous system lymphoma: spectrum of morphological MRI appearances
por: Malikova, Hana, et al.
Publicado: (2018)

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
por: Guidetti, Francesca, et al.
Publicado: (2023)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Low frequency of blood group A in secondary central nervous system lymphoma
por: Abouzari, Mehdi, et al.
Publicado: (2012)

Involvement of cranial nerves in a patient with secondary central nervous system lymphoma
por: Dantas Azevedo, Roberta, et al.
Publicado: (2016)

Could the Possibility of Secondary Central Nervous System Lymphoma Be Ruled Out in This Patient?
por: Kobayashi, Zen
Publicado: (2021)

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma
por: Yuan, Hongwei, et al.
Publicado: (2022)

A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2021)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Advances in Pathobiology of Primary Central Nervous System Lymphoma
por: Yang, Xue-Liang, et al.
Publicado: (2017)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
por: Liu, Zhuojun, et al.
Publicado: (2021)

Role of CD36 in central nervous system diseases
por: Feng, Min, et al.
Publicado: (2023)

Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma
por: da Rocha, Talita Maira Bueno da Silveira, et al.
Publicado: (2013)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8sfbjda1i7d1j92qdmv6mjph97